THC and CBD Cut TMJ Pain by 90%: The Study Changing Chronic Pain Care

A 90% Reduction in Functional Pain

For the estimated 10 million Americans living with chronic temporomandibular disorder (TMD) — the painful condition affecting the jaw joint and surrounding muscles — treatment options have long been limited to pain medications, physical therapy, mouth guards, and, in severe cases, surgery. In 2026, a clinical study from Brazilian researchers has delivered results that could reshape how chronic orofacial pain is treated: a combination of THC and CBD reduced functional pain by approximately 90%.

The study, published in the journal Clinics by researchers at Universidade Estadual Paulista and Universidade Federal de Uberlândia, represents one of the most significant cannabis pain management findings to emerge this year. Its implications extend far beyond TMD, offering new evidence for cannabis as a serious tool in chronic pain management.

Inside the Study

The research used a prospective crossover design, meaning participants underwent two consecutive treatment phases. In the first 90-day phase, participants received a placebo. In the second 90-day phase, they received a sublingual formulation containing delta-9 THC and CBD in a 1:1 ratio.

The dosing protocol was deliberately cautious. Participants started at 2 milligrams per day during the first week, with the dose gradually increasing by 2 milligrams per week until reaching 10 milligrams per day by the fifth week. This titration approach — starting low and increasing slowly — reflects best practices in cannabinoid therapy and minimizes the risk of adverse effects.

The results were remarkable across multiple measures. Average pain scores dropped from 7.35 to 3.50 on a standard 10-point pain scale. Maximum mouth opening — a key functional measure for TMD patients, many of whom struggle to open their mouths wide enough to eat normally — increased from 45.9 millimeters to 49.9 millimeters. Symptoms including allodynia (pain from normally non-painful stimuli) and hyperalgesia (heightened pain response) were nearly eliminated.

The 90% reduction in functional pain is particularly significant because functional pain — pain experienced during normal daily activities like eating, speaking, and yawning — is what most severely impacts quality of life for TMD patients. A treatment that addresses functional pain directly addresses the primary burden of the condition.

Why TMD Is So Difficult to Treat

Temporomandibular disorders encompass a range of conditions affecting the temporomandibular joint (the hinge connecting the jaw to the skull), the muscles of mastication (chewing muscles), and associated structures. Symptoms include jaw pain, facial pain, headaches, earaches, difficulty chewing, and clicking or locking of the jaw joint.

The condition is notoriously challenging to treat because its causes are multifactorial. Stress-related muscle tension, structural abnormalities, inflammation, and neurological sensitization can all contribute, often simultaneously. This means that treatments targeting a single mechanism — like NSAIDs for inflammation or muscle relaxants for tension — frequently fail to provide adequate relief.

Cannabis, with its multiple mechanisms of action, may be uniquely suited to TMD's multifactorial nature. THC and CBD interact with the endocannabinoid system, which is involved in pain modulation, inflammation regulation, muscle relaxation, and stress response — all of which are implicated in TMD.

The Broader Evidence for Cannabis and Orofacial Pain

The Brazilian TMD study does not exist in isolation. A growing body of research supports the use of cannabinoids for orofacial pain conditions. A separate randomized, double-blind pilot study published in the Journal of Clinical Medicine found that nightly application of an intraoral CBD gel significantly reduced jaw muscle activity in adults with TMD. This finding is important because nocturnal bruxism (teeth grinding during sleep) is a major contributor to TMD symptoms.

Another study examined oral CBD specifically for myofascial pain — the muscle-related component of TMD — and found improvements in jaw function, though pain reduction was less consistent. This suggests that different cannabinoids and delivery methods may be optimal for different aspects of TMD.

NORML highlighted the clinical trial results, noting that cannabis extracts significantly reduce myofascial pain in controlled research settings. The organization has called for expanded research access and clinical trials to build on these findings.

What This Means for Chronic Pain Beyond TMD

The implications of the Brazilian study extend well beyond TMD. The myofascial pain component of TMD shares mechanisms with other chronic pain conditions, including fibromyalgia, tension headaches, and chronic neck and back pain. If a 1:1 THC-to-CBD formulation can reduce functional pain by 90% in TMD patients, similar approaches may benefit millions of people suffering from other myofascial pain conditions.

The study also adds to the growing evidence that balanced THC-to-CBD ratios may be more effective for pain management than either cannabinoid alone. Research from multiple studies has suggested that CBD modulates THC's effects, potentially reducing side effects like anxiety and cognitive impairment while enhancing analgesic properties. The 1:1 ratio used in the TMD study aligns with findings from pain research in other conditions, including cancer pain and neuropathic pain.

For pain management practitioners, these results challenge the prevailing treatment paradigm. The standard approach to chronic orofacial pain — starting with over-the-counter pain relievers, escalating to prescription medications, and eventually considering surgical intervention — may need to incorporate cannabinoid therapy as an evidence-based option.

The Dosing Protocol Matters

One of the most clinically useful aspects of the study is its detailed dosing protocol. The gradual titration from 2 milligrams to 10 milligrams per day, administered sublingually, provides a practical framework that clinicians and patients can follow.

Sublingual administration (placing the cannabinoid formulation under the tongue) is a deliberate choice. This delivery method bypasses first-pass metabolism in the liver, providing more predictable absorption and faster onset compared to edibles. It also allows for more precise dosing than inhalation, which is important in a clinical context where reproducibility matters.

The final dose of 10 milligrams per day is notably modest by recreational cannabis standards. This reinforces a consistent finding across medical cannabis research: therapeutic doses are often much lower than recreational doses. For TMD patients, this means that effective pain relief may be achievable without significant psychoactive effects, particularly when using a balanced THC-to-CBD ratio.

Limitations and Caveats

No study is without limitations, and the TMD research is no exception. The crossover design, while efficient, means that all participants knew they were eventually going to receive the active treatment, which could influence placebo phase reporting. The sample size, while adequate for a clinical trial, is modest. And the 90-day treatment period, while meaningful, does not address long-term efficacy and safety.

TMD is also a condition with high placebo response rates, meaning that some of the observed improvement may not be attributable to the cannabinoid intervention alone. The researchers acknowledged this and called for larger, longer-term studies to confirm their findings.

It is also important to note that cannabis is not without risks. Even at therapeutic doses, THC can cause dizziness, dry mouth, and cognitive effects. Long-term use carries questions about tolerance, dependence, and effects on other health conditions. Patients considering cannabinoid therapy for TMD should discuss these risks with their healthcare providers.

Access and Practical Considerations

For TMD patients interested in exploring cannabinoid therapy, access remains a challenge. Cannabis is still classified as Schedule I at the federal level, and medical cannabis programs vary widely by state. Not all state programs include TMD or chronic pain as qualifying conditions, and the specific 1:1 THC-to-CBD formulation used in the study may not be readily available at all dispensaries.

Patients in states with medical cannabis programs should discuss the study's findings with their treating physicians and, if appropriate, obtain a medical cannabis recommendation specifying a balanced THC-to-CBD product. Sublingual tinctures and oils are widely available in legal markets and are the closest commercially available products to the formulation used in the study.

In states without medical cannabis programs, hemp-derived CBD products are available, but these typically lack the THC component that appears essential to the study's results. The 1:1 ratio was not an arbitrary choice — the synergy between THC and CBD is likely responsible for much of the observed benefit.

A New Chapter for Cannabis Pain Research

The Brazilian TMD study represents a broader maturation of cannabis pain research. Moving from anecdotal reports and observational studies to controlled clinical trials with specific dosing protocols and measurable outcomes is exactly the trajectory that medical cannabis advocates have been calling for.

The 90% reduction in functional pain is a headline-grabbing number, and it should grab headlines. For the millions of people living with chronic orofacial pain who have exhausted conventional treatment options, these findings offer something that has been in short supply: hope backed by clinical evidence.

As the research community continues to build on these results, and as legal frameworks evolve to improve access, cannabinoid therapy may become a standard option in the chronic pain treatment toolkit. That possibility alone makes this study one of the most important cannabis research developments of 2026.